Can Atea (NASDAQ:AVIR) Draw on Its New Loan Facility After Phase 3 Results?

Sonal Goyal

10 November 2026 06:56 PM AEDT

Can Atea (NASDAQ:AVIR) Draw on Its New Loan Facility After Phase 3 Results?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Atea announced positive topline results from the C-BEYOND Phase 3 trial in North America during the third quarter.
The company drew $65 million under a Loan agreement at closing on November 6, 2026.
Up to an additional $135 million is available under the loan agreement subject to conditions.
Cash and investments were $191.2 million at September 30, 2026.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) reported third-quarter 2026 financial results and provided a Business update, including positive topline results from C-BEYOND, its Phase 3 trial conducted in North America. The late-stage clinical biopharmaceutical company develops oral antiviral therapeutics for serious viral diseases. Atea reported cash and investments of $191.2 million at September 30, 2026, and drew $65 million under a loan agreement at closing on November 6, 2026.

Phase 3 Trial Results

During the third quarter, Atea announced positive topline results from C-BEYOND, a Phase 3 trial in North America. Topline results are the first summary of a trial's primary outcomes, released before the full data set is analyzed and published. Phase 3 trials are the final stage of testing before a regulatory submission in the United States.

The company's oral antiviral program is aimed at serious viral diseases, and the C-BEYOND trial is part of that program. The results were announced as positive in the company's business update for the quarter.

Loan Agreement

Atea entered into a loan agreement with a total capacity of up to $200 million. The company drew down $65 million at closing on November 6, 2026. Under the terms of the loan agreement, access to an additional $135 million of funding is available upon meeting certain conditions.

Loan facilities of this kind provide funding that is repaid under the terms of the agreement, which sets out the schedule and conditions for drawing additional amounts. The conditions that must be met to access the remaining $135 million are described in the company's filings.

Cash and Investments

Cash and investments were $191.2 million at September 30, 2026. The $65 million drawn at closing in November was received after the end of the quarter and is not included in the September 30 figure.

The company's cash position at the end of the quarter is the most recent Balance Sheet figure reported in the update. Quarterly spending on the company's clinical programs is reported in its full financial statements.

Final Word

Atea reported positive topline results from its C-BEYOND Phase 3 trial in North America, cash and investments of $191.2 million at September 30, 2026, and a $65 million draw under a loan Facility of up to $200 million at closing on November 6, 2026. Up to $135 million more is available under the facility subject to conditions.

FAQs

Q: What trial did Atea report results from?

A: Atea announced positive topline results from C-BEYOND, its Phase 3 trial in North America.

Q: How much did Atea draw under its loan agreement?

A: The company drew $65 million at closing on November 6, 2026.

Q: How much additional funding is available?

A: Up to $135 million of additional funding is available under the loan agreement, subject to conditions.

Q: How much cash and investments did Atea report?

A: Cash and investments were $191.2 million at September 30, 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.